Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Public ClinicalTrials.gov record NCT03317158. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Study identification
- NCT ID
- NCT03317158
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Bacillus Calmette-Guérin (BCG) Biological
- Docetaxel Drug
- Durvalumab (Cohort 1-3) Drug
- Durvalumab (Cohort 4/5) Drug
- External Beam Radiotherapy (EBRT) Radiation
- Gemcitabine Drug
- To be determined Other
- Tremelimumab Biological
Biological · Drug · Radiation + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2017
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
- Last update posted
- Apr 14, 2026
2017 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| BCG Oncology | Phoenix | Arizona | 85032 | Terminated |
| Stanford University | Stanford | California | 94305 | Withdrawn |
| Rush University Medical Cneter | Chicago | Illinois | 60612 | Withdrawn |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | Recruiting |
| Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Withdrawn |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | Recruiting |
| Columbia University Irving Medical Center | New York | New York | 10032 | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Active, not recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03317158, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03317158 live on ClinicalTrials.gov.